Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Bladder Dysfunction Reports
Published in: Current Bladder Dysfunction Reports 4/2020

01-12-2020 | Overactive Bladder | Overactive Bladder (U Lee and S Adelstein, Section Editors)

Contemporary Landmark Trials Update in the Management of Idiopathic Overactive Bladder

Authors: Emily C. Rutledge, Natalia Hernandez, Ricardo R. Gonzalez

Published in: Current Bladder Dysfunction Reports | Issue 4/2020

Login to get access

Abstract

Purpose of Review

The landmark trials evaluating the different lines of treatment for overactive bladder (OAB) were reviewed to provide a summary of the most recent advances in behavioral, medical, and surgical management of OAB in the last 5 to 10 years.

Recent Findings

Clinical trials for the treatment of OAB have evaluated the efficacy and effectiveness of different combinations of medical management, surgical management, and conservative therapies in quality of life improvement in these patients. All three lines of therapy include safe and effective treatment options that can be used as monotherapy or in combination to treat a variety of patient characteristics and comorbidities.

Summary

The three lines of treatment currently available to patients continue to be improved with new innovations in strategies for their use in combination with one another and improving technology to make them safer, more effective, and individualized to each patient’s needs.
Literature
1.
Ganz ML, Smalarz AM, Krupski TL, Anger JT, Hu JC, Wittrup-Jensen KU, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75:526–32 532.e1–18.CrossRef
2.
Sexton CC, Coyne KS, Thompson C, Bavendam T, Chen C-I, Markland A. Prevalence and effect on health-related quality of life of overactive bladder in older Americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc. 2011;59:1465–70.CrossRef
3.
Pratt TS, Suskind AM. Management of overactive bladder in older women. Curr Urol Rep. 2018;19:92.CrossRef
4.
de Boer TA, Slieker-ten Hove MCP, Burger CW, Vierhout ME. The prevalence and risk factors of overactive bladder symptoms and its relation to pelvic organ prolapse symptoms in a general female population. Int Urogynecol J. 2011;22:569–75.CrossRef
5.
Gormley EA, Lightner DJ, Faraday M, Vasavada SP, American Urological Association, Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193:1572–80.CrossRef
6.
Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016;215:704–11.CrossRef
7.
Nanette Santoro IL (2018) Genitourinary syndrome of menopause: Underdiagnosed and undertreated. Contemporary OB/GYN 64:10–13, 23.
8.
Harvie HS, Amundsen CL, Neuwahl SJ, Honeycutt AA, Lukacz ES, Sung VW, et al. Cost-effectiveness of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: results of the ROSETTA randomized trial. J Urol. 2020;203:969–77.CrossRef
9.
Murray B, Hessami SH, Gultyaev D, Lister J, Dmochowski R, Gillard KK, et al. Cost-effectiveness of overactive bladder treatments: from the US payer perspective. J Comp Eff Res. 2019;8:61–71.CrossRef
10.
Voorham JC, De Wachter S, Van den Bos TWL, Putter H, Lycklama À, Nijeholt GA, et al. The effect of EMG biofeedback assisted pelvic floor muscle therapy on symptoms of the overactive bladder syndrome in women: a randomized controlled trial. Neurourol Urodyn. 2017;36:1796–803.CrossRef
11.
•• Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019. https://​doi.​org/​10.​1001/​jamainternmed.​2019.​0677This reference is important as it brought to light the important concern of cognitive effects from anticholinergics.
12.
Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol. 2012;62:834–40.CrossRef
13.
Michel MC. β-adrenergic receptor subtypes in the urinary tract. Handb Exp Pharmacol. 2011:307–18.
14.
MacDiarmid S, Al-Shukri S, Barkin J, Fianu-Jonasson A, Grise P, Herschorn S, et al. Mirabegron as add-on treatment to solifenacin in patients with incontinent overactive bladder and an inadequate response to solifenacin monotherapy. J Urol. 2016;196:809–18.CrossRef
15.
Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol. 2016:136–45. https://​doi.​org/​10.​1016/​j.​eururo.​2016.​02.​030.
16.
• Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee K-S, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120:562–75 This reference was practice changing as it brought strong evidence to the strategy of using combination oral medications.CrossRef
17.
• Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, et al. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II). Eur Urol. 2018;74:501–9 This reference provided further evidence of the value of combination therapy.CrossRef
18.
Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67:577–88.CrossRef
19.
Ellington DR, Szychowski JM, Malek JM, Gerten KA, Burgio KL, Richter HE. Combined tolterodine and vaginal estradiol cream for overactive bladder symptoms after randomized single-therapy treatment. Female Pelvic Med Reconstr Surg. 2016;22:254–60.CrossRef
20.
Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010:1438–43. https://​doi.​org/​10.​1016/​j.​juro.​2009.​12.​036.
21.
Marchal C, Herrera B, Antuña F, Saez F, Perez J, Castillo E, et al. Percutaneous tibial nerve stimulation in treatment of overactive bladder: when should retreatment be started? Urology. 2011;78:1046–50.CrossRef
22.
Sherif H, Abdelwahab O. Posterior tibial nerve stimulation as treatment for the overactive bladder. Arab J Urol. 2013;11:131–5.CrossRef
23.
Lee W-C, Chuang Y-C. Mechanism of action of onabotulinumtoxinA on lower urinary tract dysfunction. Tzu Chi Med J. 2014;26:1–4.CrossRef
24.
Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184:2416–22.CrossRef
25.
Orasanu B, Mahajan ST. The use of botulinum toxin for the treatment of overactive bladder syndrome. Indian J Urol. 2013;29:2–11.CrossRef
26.
•• Amundsen CL, Komesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF, et al. Two-year outcomes of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial. Eur Urol. 2018;74:66–73 This reference provided longer term data comparing third line treatments.CrossRef
27.
Nitti VW, Ginsberg D, Sievert K-D, Sussman D, Radomski S, Sand P, et al. Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study. J Urol. 2016;196:791–800.CrossRef
28.
Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MFR, Menefee SA, et al. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med. 2012;367:1803–13.CrossRef
29.
Chapple C, Sievert K-D, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64:249–56.CrossRef
30.
Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189:2186–93.CrossRef
31.
Kennelly M, Green L, Alvandi N, Wehbe S, Smith JJ 3rd, MacDiarmid S, et al. Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settings. Curr Med Res Opin. 2018;34:1771–6.CrossRef
32.
Liao C-H, Kuo H-C. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. J Urol. 2013;189:1804–10.CrossRef
33.
Kuo H-C. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn. 2011;30:1242–8.PubMed
34.
Hassouna MM, Siegel SW, Nÿeholt AA, Elhilali MM, van Kerrebroeck PE, Das AK, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol. 2000;163:1849–54.CrossRef
35.
Schmidt RA, Jonas UDO, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. J Urol. 1999;162:352–7.CrossRef
36.
Elterman DS. The novel Axonics® rechargeable sacral neuromodulation system: procedural and technical impressions from an initial North American experience. Neurourol Urodyn. 2018;37:S1–8.CrossRef
37.
Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34:224–30.CrossRef
38.
•• McCrery R, Lane F, Benson K, Taylor C, Padron O, Blok B, et al. Treatment of urinary urgency incontinence using a rechargeable SNM system: 6-month results of the ARTISAN-SNM study. J Urol. 2020;203:185–92 This reference was a landmark study publishing results of a rechargeable SNM device.CrossRef
39.
• Benson K, McCrery R, Taylor C, Padron O, Blok B, Wachter S, et al. One-year outcomes of the ARTISAN-SNM study with the Axonics System for the treatment of urinary urgency incontinence. Neurourol Urodyn. 2020;56:581 This reference provided longer term outcomes for rechargeable SNM device.
40.
Noblett K, Benson K, Kreder K. Detailed analysis of adverse events and surgical interventions in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients. Neurourol Urodyn. 2017:1136–9. https://​doi.​org/​10.​1002/​nau.​23076.
Metadata
Title
Contemporary Landmark Trials Update in the Management of Idiopathic Overactive Bladder
Authors
Emily C. Rutledge
Natalia Hernandez
Ricardo R. Gonzalez
Publication date
01-12-2020
Publisher
Springer US
Published in
Current Bladder Dysfunction Reports / Issue 4/2020
Print ISSN: 1931-7212
Electronic ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-020-00617-w

Other articles of this Issue 4/2020

Current Bladder Dysfunction Reports 4/2020 Go to the issue

Voiding Dysfunction Evaluation (B Brucker and B Peyronnet, Section Editors)

The Role of Pelvic Neurophysiology Testing in the Assessment of Patients with Voiding Dysfunction

Voiding Dysfunction Evaluation (B Brucker and B Peyronnet, Section Editors)

Urodynamics for the “Failed” Midurethral Sling

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Management of Pelvic Floor Disorders in Young Women

Neurogenic Bladder (C Powell, Section Editor)

Sexual Health in the Neurogenic Patient

Global Health (Kurt McCammon, Section Editor)

Cost-Effectiveness and Economic Benefits of Volunteerism

Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

Management of Chronic Bacteriuria in Neurogenic Bladders